Status:

COMPLETED

Nutrition, Exercise, and Breast Cancer Survivorship

Lead Sponsor:

Baltimore VA Medical Center

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Breast Cancer Survivorship

Sarcopenia

Eligibility:

FEMALE

45-80 years

Phase:

NA

Brief Summary

The purpose of the study is to examine the effects of resistance training on the reasons (mechanisms) underlying the development of fatigue, muscle weakness and wasting (sarcopenia), and impaired phys...

Detailed Description

Breast cancer is the most frequently diagnosed cancer in women, representing 26% of all female cancers. It is also the second leading cause of cancer related deaths in the US for women. Side effects o...

Eligibility Criteria

Inclusion

  • Histologic evidence of previous breast cancer
  • Three months post active cancer therapy (i.e. radiation/chemotherapy)
  • Non smoker (non smoking for at least 12 months: cigarettes, cigars, pipes)
  • 45-80 years of age
  • Menopause over one year (absence of menses for 12 months or greater)
  • Sedentary lifestyle (structured physical activity \</= 2x per week)
  • BMI \>/=18 and \<50 kg/m2

Exclusion

  • Unstable lymphedema (no intensive therapy, no recorded 10% change in arm volume or circumference, no more than one lymphedema-related infection requiring antibiotics and no change in ADLs due to a lymphedema exacerbation for the past 3 months)
  • Plans for surgery (e.g., breast reconstruction) during the study period
  • Evidence of recurrent cancer or metastases
  • Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (SBP over 180 mm HG) unless medically stabilized
  • Abnormal renal function (BUN above 40 mg/dl, Cr above 1.3 mg/dl, CrCl\<60mg/dl)
  • Anemia HCT below 30 mg/dl, platelets below 100,000/cm3
  • History of seizures or taking anti-seizure or anti convulsion medication
  • Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)
  • Allergic to lidocaine
  • Abnormal liver function
  • Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120 mm HG, or other contraindications to exercise) confirmed with further diagnostic evaluations.
  • Type 1 diabetes; insulin treatment for diabetes, poorly controlled diabetes, HgA1c\>10%
  • Taking oral steroids, warfarin, or other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (i.e. for 72 hours prior)
  • MMSE below 24, dementia, or unstable clinical depression by exam
  • Chronic pulmonary disease (on supplemental O2)
  • Metal implants or devices (i.e. pacemaker) if undergoing CT scan
  • Participant is, in the opinion of the investigator, unable to adhere to the study protocol due to medical or orthopedic conditions that limit ability to exercise or travel to the Baltimore VA for protocol procedures
  • Aerobically trained with VO2max greater than 2 SD above age-adjusted mean
  • Alcohol consumption greater than 3 oz. liquor, 3x4 oz glass of wine, or 2x12 oz beers per day, by self report

Key Trial Info

Start Date :

May 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 6 2016

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT01151488

Start Date

May 1 2012

End Date

December 6 2016

Last Update

February 1 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Baltimore VAMC

Baltimore, Maryland, United States, 21201